Handelsavisen
prelaunch
Companies ›Healthcare ›VIT.AX
VI
VIT.AX — ASX Pharmaceuticals

Vitura Health Ltd

A$0,03
Open in Charts → Attach watcher ⌖
— —
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
7,33 %
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Vitura Health Ltd is a healthcare company engaged in the pharmaceuticals and medical research industry, primarily generating revenue through the development and commercialization of pharmaceutical products.

Business. Vitura Health Ltd (VIT.AX) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VIT.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VIT.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Vitura Health Ltd (VIT.AX) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED
    — missing data
    Key takeaways
    • Vitura Health Ltd has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
    • The company's liquidity risk is unassessed due to missing balance-sheet data and no going-concern language in source documents.
    • Profitability and return metrics are not available, making it difficult to evaluate performance against industry benchmarks.
    • Revenue concentration and geographic exposure are not disclosed, limiting the understanding of regional risk exposure.
    • Growth trajectory and historical revenue data are missing, preventing meaningful projections or market position analysis.
    • Recent events and strategic developments are not disclosed, reducing visibility into management's actions and responses to market conditions.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-08-29
    FY 2024 · Full-year highlights

    Revenue A$123.9M, +5,6% YoY; Operating income −77,2% YoY.

    RevenueA$123.9M+5,6 % YoY
    Operating incomeA$4.6M−77,2 % YoY
    Net incomeA$3.5M−74,6 % YoY
    Free cash flow-A$1.3M−116,0 % YoY
    EPS—
    Operating cash flowA$7.0M−27,9 % YoY
    Financials
    Income statement
    RevenueA$123.9M
    Gross profitA$34.2M
    Operating incomeA$4.6M
    Net incomeA$3.5M
    Margins
    Gross margin27.6%
    Operating margin3.7%
    Net margin2.8%
    FCF margin-1.1%
    Balance sheet
    Total assetsA$71.3M
    Total liabilitiesA$32.5M
    Total equityA$38.8M
    Cash & equivalents—
    Long-term debtA$11.0M
    Cash flow
    Operating cash flowA$7.0M
    CapEx-A$786.4k
    Free cash flow-A$1.3M
    SBC—
    P&L flow · revenue → net income
    Revenue A$123.9MOperating costs A$119.3MTax A$1.1MNet income A$3.5M
    Highlights
    • ▍Revenue A$123.9M, +5,6% YoY
    • ▍Operating income −77,2% YoY
    • ▍Net income −74,6% YoY
    • ▍Free cash flow −116,0% YoY
    • ▍Net margin 2.8%

    Valuation FY

    Market price
    A$0,03
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Vitura Health Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VIT.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-08-29 11:37 UTCEARNINGSAnnual results — FY 2024 Revenue AUD 123.9M · Net AUD 3.5M
    2023-08-23 03:24 UTCEARNINGSAnnual results — FY 2023 Revenue AUD 117.3M · Net AUD 13.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage